In this study, we used Taiwan’s National Health Insurance database to assess the association between SGLT2 inhibitor use and the risk of gout incidence compared with use of dipeptidyl peptidase 4 (DPP4) inhibitors in patients with T2DM. Here, SLC5A2 is linked to type 2 diabetes mellitus.